Ab Dilli door nahi: Ranjan Pai is paying a hefty price for Medanta to break his northern jinx
- After multiple unsuccessful attempts to break into the critical north Indian market, Manipal is placing a seemingly expensive bet on Medanta.
- Manipal’s investors are nearing their exit windows, increasing the pressure on the company to deliver returns.
- Other prominent hospital chains, including NH and HCG, have taken the same route in an industry struggling for growth.
Read the full article nowBecome a member
The latest from ET Prime is now on Telegram. To subscribe to our Telegram newsletter click here.
Subscribe to ET Prime
trial period + Free Cancellation within trial period
Gift this story
Maximum 10 Email IDs allowed
300 characters remaining
Gift Sent Successfully
You’ve gifted all the 0 articles from your monthly gift bucket!
Please come back next month.
0 more articles will be waiting for you in your gift bucket.